These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 9873793)

  • 1. Factor VIII immunogenicity.
    Jacquemin MG; Saint-Remy JM
    Haemophilia; 1998 Jul; 4(4):552-7. PubMed ID: 9873793
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunogenicity and immune tolerance coagulation Factors VIII and IX.
    Rup B
    Dev Biol (Basel); 2003; 112():55-9. PubMed ID: 12762504
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hemophilia factor VIII therapy. Immunological tolerance. A clinical perspective.
    White GC; Greenwood R; Escobar M; Frelinger JA
    Haematologica; 2000 Oct; 85(10 Suppl):113-6. PubMed ID: 11187862
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Origin and nature of the neutralizing immune response against therapeutic factor VIII].
    Bou Jaoudeh M; Delignat S; Varthaman A; Lacroix-Desmazes S
    Med Sci (Paris); 2020 Apr; 36(4):341-347. PubMed ID: 32356710
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Induction of immune tolerance with factor VIII concentrate in patients with hemophilia A and inhibitors.
    Ewing NP
    Prog Clin Biol Res; 1990; 324():59-68. PubMed ID: 2106693
    [No Abstract]   [Full Text] [Related]  

  • 6. Induction of tolerance using porcine factor VIII.
    Hay CR; Laurian Y
    Vox Sang; 1996; 70 Suppl 1():68-9. PubMed ID: 8869473
    [No Abstract]   [Full Text] [Related]  

  • 7. Immune tolerance in haemophilia and the treatment of haemophiliacs with an inhibitor. Proceedings of the 2nd Workshop on Immune Tolerance. Bonn-Konigswinter, Germany, August 27-30, 1997.
    Vox Sang; 1999; 77 Suppl 1():1-100. PubMed ID: 10644229
    [No Abstract]   [Full Text] [Related]  

  • 8. Domain specificity of factor VIII inhibitors during immune tolerance induction in patients with haemophilia A.
    van Helden PM; Kaijen PH; Mauser-Bunschoten EP; Fischer K; van den Berg HM; Voorberg J
    Haemophilia; 2010 Nov; 16(6):892-901. PubMed ID: 20491952
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mechanisms of action of immune tolerance induction against factor VIII in patients with congenital haemophilia A and factor VIII inhibitors.
    Reipert BM; van Helden PM; Schwarz HP; Hausl C
    Br J Haematol; 2007 Jan; 136(1):12-25. PubMed ID: 17222196
    [TBL] [Abstract][Full Text] [Related]  

  • 10. First-line immune tolerance induction for children with severe haemophilia A: A protocol from the UK Haemophilia Centre Doctors' Organisation Inhibitor and Paediatric Working Parties.
    Collins P; Chalmers E; Alamelu J; Hay C; Liesner R; Makris M; Mathias M; Payne J; Rangarajan S; Richards M; Talks K; Tunstall O; Williams M; Hart DP
    Haemophilia; 2017 Sep; 23(5):654-659. PubMed ID: 28574205
    [No Abstract]   [Full Text] [Related]  

  • 11. Immunological and laboratory aspects of immune tolerance.
    Kazatchkine M; Hoyer L
    Vox Sang; 1996; 70 Suppl 1():52-9. PubMed ID: 8869470
    [No Abstract]   [Full Text] [Related]  

  • 12. Immune tolerance in hemophilia and the treatment of hemophiliacs with an inhibitor. Proceedings of a meeting. Palermo, Italy, October 1999.
    Haematologica; 2000 Oct; 85(10 Suppl):1-116. PubMed ID: 11236744
    [No Abstract]   [Full Text] [Related]  

  • 13. Summary report of the First International Conference on inhibitors in haemophilia A.
    Lacroix-Desmazes S; Scott DW; Goudemand J; Van Den Berg M; Makris M; Van Velzen AS; Santagostino E; Lillicrap D; Rosendaal FR; Hilger A; Sauna ZE; Oldenburg J; Mantovani L; Mancuso ME; Kessler C; Hay CRM; Knoebl P; Di Minno G; Hoots K; Bok A; Brooker M; Buoso E; Mannucci PM; Peyvandi F
    Blood Transfus; 2017 Oct; 15(6):568-576. PubMed ID: 27893354
    [No Abstract]   [Full Text] [Related]  

  • 14. Immune tolerance induction with a factor VIII concentrate containing von Willebrand factor (Haemoctin SDH®) in 14 patients with severe haemophilia A.
    Bidlingmaier C; Kurnik K; Escuriola-Ettingshausen C; Jager R; Klamroth R; Male C; Marosi A; Nemes L; von Stackelberg A; Kreuz W
    Haemophilia; 2011 Sep; 17(5):e837-40. PubMed ID: 21649797
    [No Abstract]   [Full Text] [Related]  

  • 15. Immune tolerance therapy in patients with acquired hemophilia.
    von Depka M
    Hematology; 2004 Aug; 9(4):245-57. PubMed ID: 15621732
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Factor VIII brand and immunogenicity.
    Ragni MV
    Blood; 2014 Nov; 124(23):3337-8. PubMed ID: 25431473
    [No Abstract]   [Full Text] [Related]  

  • 17. Adult haemophilia A patients with inhibitors: successful immune tolerance induction with a single FVIII/VWF product.
    Rangarajan S; Jiménez-Yuste V; Santagostino E
    Haemophilia; 2014 Nov; 20(6):e414-7. PubMed ID: 25333452
    [No Abstract]   [Full Text] [Related]  

  • 18. Antibodies to factor VIII in hemophilia A patients.
    Brackmann HH; Schwaab R; Effenberger W; Hess L; Hanfland P; Oldenburg J
    Vox Sang; 2000; 78 Suppl 2():187-90. PubMed ID: 10938950
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibitor development in prospective clinical trials with recombinant factor VIII preparations in previously untreated patients.
    Lusher JM
    Vox Sang; 1999; 77 Suppl 1():9. PubMed ID: 10529677
    [No Abstract]   [Full Text] [Related]  

  • 20. Immunological aspects of inhibitor development.
    Reding MT
    Haemophilia; 2006 Dec; 12 Suppl 6():30-5; discussion 35-6. PubMed ID: 17123391
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.